Clinical Trial

A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

Study acronym: CATTALYST
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the clinical adoption, treatment patterns, and safety of adjuvant ribociclib use in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) patients. This is a multi-country study using secondary real-world data sources.
Trial Details
NCT Number NCT07710716
Lead Sponsor Novartis Pharmaceuticals
Conditions Breast Cancer
Enrollment 3,000 participants
Start Date 2026-04-09
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-17